論文・技術情報追加のお知らせ

①A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS).

チザニジンとCYP1A2阻害剤の薬物相互作用の不均衡分析研究

対象DB：FAERS

②Safety of fexofenadine and other second-generation oral antihistamines before and after the removal of the prescription requirement in Italy and other European countries: A real-world evidence study and systematic review.

欧州諸国における処方要件撤廃前後の第2世代経口抗ヒスタミン薬安全性プロファイル研究

対象DB：FAERS

③A Possible Case of COVID-19 Booster Vaccine-Associated Rhabdomyolysis and Acute Kidney Injury.

COVID-19ブースターワクチンによる横紋筋融解症および急性腎不全調査

対象DB：VAERS

④Ocrelizumab-related neutropenia: Effects of age, sex and bodyweight using the FDA Adverse Event Reporting System (FAERS).

オクレリズマブ関連の好中球減少症リスク因子探索研究

対象DB：FAERS

⑤Risk factors for suicidal behavior/ideation and hostility/aggression in patients with bipolar disorders: An analysis using the Japanese Adverse Drug Event Report database.

双極性障害患者における自殺傾向および敵意/攻撃性の危険因子調査

対象DB：JADER

⑥Comparative assessment of myocarditis and pericarditis reporting rates related to mRNA COVID-19 vaccines in Europe and the United States.

COVID-19 mRNAワクチンに関する心筋炎および心膜炎報告率の比較評価研究

対象DB：EudraVigilance,VAERS

⑦Adverse drug reactions associated with doxorubicin and epirubicin: A descriptive analysis from VigiBase.

ドキソルビシンおよびエピルビシンに関連する副作用調査研究

対象DB：VigiBase

⑧Medications as a Trigger of Sleep-Related Eating Disorder: A Disproportionality Analysis.

睡眠関連摂食障害の誘因としての薬物療法評価研究

対象DB：VigiBase